EyePoint Pharmaceuticals/$EYPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Ticker

$EYPT
Primary listing

Industry

Pharmaceuticals

Employees

165

ISIN

US30233G2093

EYPT Metrics

BasicAdvanced
$614M
-
-$2.43
1.60
-

What the Analysts think about EYPT

Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.

Bulls say / Bears say

EyePoint Pharmaceuticals has a strong cash position of $371 million as of December 31, 2024, providing a runway into 2027, which supports ongoing clinical trials and operations. (stocktitan.net)
The company's lead product candidate, DURAVYU, is in Phase 3 clinical trials for wet AMD, with topline data expected in 2026, potentially leading to significant market opportunities. (biospace.com)
Analysts have a consensus 'Strong Buy' rating for EYPT, with a price target of $24.00, indicating confidence in the company's growth prospects. (stockanalysis.com)
EyePoint reported a net loss of $130.9 million in 2024, an 84.9% increase from the previous year, raising concerns about financial sustainability. (stocktitan.net)
An FDA warning letter regarding manufacturing violations at the Watertown facility introduces risks that could impact product supply and future approvals. (panabee.com)
The company's operating expenses increased to $189.1 million in 2024, primarily due to higher clinical trial costs and personnel expenses, which may pressure profitability. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

EYPT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

EYPT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EYPT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs